American Oriental Bioengineering to Launch New Prescription Pai Du Qing Zhi Tablet

NEW YORK, Aug. 9 /PRNewswire-Asia-FirstCall/ -- American Oriental Bioengineering, Inc. (NYSE: AOB), ("the Company" or "AOBO"), a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter ("OTC") products, today announced that its Boke brand Pai Du Qing Zhi Tablet, ("PDQZ Tablet"), a prescription medicine aimed at achieving the balance of Yin Yang by regulating metabolism, in order to cleanse the blood and detoxify, dispose of hemorrhoids, fight obesity and lower hyperlipemia, will be commercially launched in the third quarter of 2010. The Company completed successful test marketing in the second quarter of 2010.

The Company will launch the PDQZ Tablet under its well-established Boke brand to leverage market recognition for the brand. Boke, a wholly owned subsidiary of the Company, has become a recognized and trusted brand through the popularity and increasing sales of its all-natural Boke Nasal Spray. Like Boke Nasal Spray, Boke PDQZ Tablet will also be formulated from all natural ingredients, such as botanical extractions and excipients.

Mr. Tony Liu commented, "The successful launch of the PDQZ Tablet marks a milestone for our R&D team. We believe this milestone marks only the beginning of many future success projects to come."

About American Oriental Bioengineering, Inc.

American Oriental Bioengineering, Inc. is a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter products.

Forward-Looking Statements

Statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that may cause actual results to differ materially from those set forth in these statements. The economic, competitive, governmental, technological and other factors identified in the Company's filings with the Securities and Exchange Commission, including the Form 10-K for the year ended December 31, 2010, may cause actual results or events to differ materially from those described in the forward looking statements in this press release. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise.

    For more information, please contact:

     ICR, LLC
     Christine Duan or Ashley Ammon
     Phone: +1-646-277-1200

SOURCE American Oriental Bioengineering, Inc.